Literature DB >> 4000498

Methysergide in progressive supranuclear palsy.

A S Duncombe, A J Lees.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4000498     DOI： 10.1212/wnl.35.6.936

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  5 in total

1.  Treatment of progressive supranuclear palsy with methysergide. A clinical study.

Authors:  G Di Trapani; P Stampatore; A La Cara; A Azzoni; M L Vaccario
Journal:  Ital J Neurol Sci       Date:  1991-04

Review 2.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

Review 4.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

Review 5.  Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Authors:  Brent Bluett; Alexander Y Pantelyat; Irene Litvan; Farwa Ali; Diana Apetauerova; Danny Bega; Lisa Bloom; James Bower; Adam L Boxer; Marian L Dale; Rohit Dhall; Antoine Duquette; Hubert H Fernandez; Jori E Fleisher; Murray Grossman; Michael Howell; Diana R Kerwin; Julie Leegwater-Kim; Christiane Lepage; Peter Alexander Ljubenkov; Martina Mancini; Nikolaus R McFarland; Paolo Moretti; Erica Myrick; Pritika Patel; Laura S Plummer; Federico Rodriguez-Porcel; Julio Rojas; Christos Sidiropoulos; Miriam Sklerov; Leonard L Sokol; Paul J Tuite; Lawren VandeVrede; Jennifer Wilhelm; Anne-Marie A Wills; Tao Xie; Lawrence I Golbe
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.